Method for the treatment of Dravet Syndrome
US-12097206-B2 · Sep 24, 2024 · US
Sphingosine kinase type 1 inhibitors
US9388121B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9388121-B2 |
| Application number | US-201213649221-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 11, 2012 |
| Priority date | Apr 29, 2008 |
| Publication date | Jul 12, 2016 |
| Grant date | Jul 12, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating tumors of the central nervous system, e.g., glioblastoma (GBM).
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from or a pharmaceutically acceptable salt thereof, wherein R is selected from a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing. 2. The compound of claim 1 having the structure 3. The compound of claim 1 having the structure 4. The compound of claim 1 having the structure 5. The compound of claim 1 having the structure 6. The compound of claim 1 having the structure 7. The compound of claim 1 having the structure 8. The compound of claim 1 having the structure 9. The compound of claim 8 , wherein R is 3,4-dimethoxy. 10. The compound of claim 8 , wherein R is 4-phenyl. 11. The compound of claim 8 , wherein R is 3-pentyl. 12. The compound of claim 1 , wherein the compound inhibits sphingosine kinase 1 greater than sphingosine kinase 2.
Assignees
Inventors
Classifications
- A61K31/135Primary
having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)} · CPC title
- C07C215/28Primary
and containing six-membered aromatic rings · CPC title
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil · CPC title
with aromatic radicals attached to the chain · CPC title
having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9388121B2 cover?
- Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating tumors of the central nervous system, e.g., glioblastoma (GBM).
- Who is the assignee on this patent?
- Enzo Therapeutics Inc, Univ Virginia Commonwealth
- What technology area does this patent fall under?
- Primary CPC classification A61K31/135. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).